Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law
Brighter Future After 2019 Challenges?
Executive Summary
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.
You may also be interested in...
Asia Deal Watch: BeiGene Gets Chinese Rights To Two EUSA Rare Disease Therapies
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
Voronoi In Spotlight For Brain-Permeable Lung Cancer Candidate
South Korea’s unicorn biotech Voronoi is counting on its novel lung cancer therapy to become a game changer in the market thanks to its high target selectivity and brain permeability.
Korean Biotech Sentiment Still Shaky But IPO Recovery Seen By Year-End
After a lackluster year so far for South Korean biotech IPOs amid disappointing clinical trial news, investor interest is beginning to pick up, with several companies that have been under the spotlight slated to debut on the market in the coming months.